Use of Diterpene Ginkgolides Meglumine Injection to Regulate Plasma Levels of PAI-1 and t-PA in Patients With Acute Atherosclerotic Cerebral Infarction
| Autor: | Yuqian Wang, Rui Chen, Liandong Zhao, Jie Xu, Ying Zhao, Luxia Yan, Peng Xie, Jisha Tian, Yue Liu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Tissue plasminogen activator Gastroenterology Brain Ischemia Meglumine Internal medicine Fibrinolysis Plasminogen Activator Inhibitor 1 medicine Humans Ginkgolides medicine.diagnostic_test business.industry Cerebral infarction Cerebral Infarction medicine.disease Thromboelastography Stroke Coagulation Tissue Plasminogen Activator Acute Disease business Plasminogen activator medicine.drug |
| Zdroj: | The neurologist. 27(6) |
| ISSN: | 2331-2637 |
| Popis: | BACKGROUND To: (i) explore the effect of diterpene ginkgolides meglumine injection (DGMI) on neurological deficit symptoms in acute atherosclerotic cerebral infarction (AACI) patients; (ii) measure the level of plasma plasminogen activator inhibitor (PAI)-1 and tissue plasminogen activator (t-PA). METHODS Eighty AACI patients were divided equally and randomly into the DGMI group and control group. In addition to basic treatment, the DGMI group was treated with DGMI (25 mg/d) for 14 days. The control group had basic treatment without DGMI. Before and after treatment, the degree of neurological deficit was assessed, thromboelastography undertaken, and plasma levels of PAI-1 and t-PA measured. RESULTS The National Institutes of Health Stroke Scale score of patients in the DGMI group after treatment was lower than that in the control group, and the Barthel Index was higher than that in the control group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|